Presentation by Richard D. Hurt, M.D., chair of Global Bridges and founding director of the Mayo Clinic Nicotine Dependence Center, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Members of the Content Marketing Association (CMA) have helped their clients migrate to tablet since their arrival. The CMA recently undertook research focusing on how businesses use tablets to consume news, business documents and corporate reports. For the first time, Patrick Fuller, CEO of the CMA, shares the findings with non-CMA members.
Presented in Broadband World Forum 2011, it intends to introduce conceipts about QoS, QoE, related standards and the challenges for service quality measurements and meeting customer expectations
Members of the Content Marketing Association (CMA) have helped their clients migrate to tablet since their arrival. The CMA recently undertook research focusing on how businesses use tablets to consume news, business documents and corporate reports. For the first time, Patrick Fuller, CEO of the CMA, shares the findings with non-CMA members.
Presented in Broadband World Forum 2011, it intends to introduce conceipts about QoS, QoE, related standards and the challenges for service quality measurements and meeting customer expectations
ES el. komercijos statistiniai duomenys, 2011 m.Saulius Dackys
Pateikiame ES institucijų, renginiui Digital Agenda Assembly 2012, surinktus statistinius duomenis apie bandrą situaciją el. komercijos rinkoje. Juose puikiai matosi kokioje vietoje yra el. komercija Lietuvoje. Džiugu tai, kad turime kur dirbti.
Borderless Digital Commerce - Walter Devenuto, President EMOTAWalter Devenuto
Opening Presentation at the International E-Commerce Forum in Barcelona on 14th March 2013, with up-to-date stastistics on the European e-commerce market, most important trends and best practices in international online retail, and an overview of EMOTA lobbying activities for e-commerce with the European Union institutions
Hoe staat het er voor qua omzet en verdeling binnen affiliate marketing in Nederland? Het IAB heeft in samenwerking met Deloitte een onderzoek gedaan en zal de resultaten traditioneel op de Affiliate Dag bekend maken!
Challenges to Tobacco Dependence Treatment in Europe -- Hayden McRobbie, M.B....Global Bridges
Presentation by Hayden McRobbie, M.B., Ch.B., Ph.D., Auckland University of Technology, New Zealand, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Challenges in Expanding the Role of Health Care Providers and Delivering Trea...Global Bridges
Presentation by Lekan Ayo-Yusuf, D.D.S., M.P.H., Ph.D., regional director of the Global Bridges African region, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
The Critical Importance of Health Care Worker Leadership in the Tobacco Contr...Global Bridges
Presentation by Eduardo Bianco, M.D., Framework Convention Alliance, Uruguay, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Competence-Based Training for a National Stop-Smoking Service: An English Cas...Global Bridges
Presentation by Andy McEwen, Ph.D., National Centre for Smoking Cessation and Training, UK, at the 15th World Conference on Tobacco OR Health in Singapore.
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Pharmacotherapy for Tobacco Dependence -- Richard D. Hurt, M.D., Mayo ClinicGlobal Bridges
On April 4, 2012, Global Bridges presented the webinar "Pharmacotherapy for Tobacco Dependence," which featured Richard D. Hurt, M.D., founder and director of the Mayo Clinic Nicotine Dependence Center.
For the audio/video from this presentation, please visit http://www.youtube.com/watch?v=NqndR9wWfZo
Presentation given at the WTO during an ICTSD dialogue on the current situation of the Doha Round (22nd March 2010).
Different quantitative estimates are presented based on research conducted at IFPRI and the World Bank.
Papers quoted in this presentation can be downloaded from http://www.ifpri.org/book-6308/ourwork/researcharea/doha-round
ES el. komercijos statistiniai duomenys, 2011 m.Saulius Dackys
Pateikiame ES institucijų, renginiui Digital Agenda Assembly 2012, surinktus statistinius duomenis apie bandrą situaciją el. komercijos rinkoje. Juose puikiai matosi kokioje vietoje yra el. komercija Lietuvoje. Džiugu tai, kad turime kur dirbti.
Borderless Digital Commerce - Walter Devenuto, President EMOTAWalter Devenuto
Opening Presentation at the International E-Commerce Forum in Barcelona on 14th March 2013, with up-to-date stastistics on the European e-commerce market, most important trends and best practices in international online retail, and an overview of EMOTA lobbying activities for e-commerce with the European Union institutions
Hoe staat het er voor qua omzet en verdeling binnen affiliate marketing in Nederland? Het IAB heeft in samenwerking met Deloitte een onderzoek gedaan en zal de resultaten traditioneel op de Affiliate Dag bekend maken!
Challenges to Tobacco Dependence Treatment in Europe -- Hayden McRobbie, M.B....Global Bridges
Presentation by Hayden McRobbie, M.B., Ch.B., Ph.D., Auckland University of Technology, New Zealand, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Challenges in Expanding the Role of Health Care Providers and Delivering Trea...Global Bridges
Presentation by Lekan Ayo-Yusuf, D.D.S., M.P.H., Ph.D., regional director of the Global Bridges African region, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
The Critical Importance of Health Care Worker Leadership in the Tobacco Contr...Global Bridges
Presentation by Eduardo Bianco, M.D., Framework Convention Alliance, Uruguay, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Competence-Based Training for a National Stop-Smoking Service: An English Cas...Global Bridges
Presentation by Andy McEwen, Ph.D., National Centre for Smoking Cessation and Training, UK, at the 15th World Conference on Tobacco OR Health in Singapore.
Overview of Tobacco Treatment Provisions at a National Level -- Martin RawGlobal Bridges
Presentation by Martin Raw, UK Centre for Tobacco Control Studies and National Institute of Alcohol and Drug Policies, Brazil, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Pharmacotherapy for Tobacco Dependence -- Richard D. Hurt, M.D., Mayo ClinicGlobal Bridges
On April 4, 2012, Global Bridges presented the webinar "Pharmacotherapy for Tobacco Dependence," which featured Richard D. Hurt, M.D., founder and director of the Mayo Clinic Nicotine Dependence Center.
For the audio/video from this presentation, please visit http://www.youtube.com/watch?v=NqndR9wWfZo
Presentation given at the WTO during an ICTSD dialogue on the current situation of the Doha Round (22nd March 2010).
Different quantitative estimates are presented based on research conducted at IFPRI and the World Bank.
Papers quoted in this presentation can be downloaded from http://www.ifpri.org/book-6308/ourwork/researcharea/doha-round
Webinar: Waterpipe use from the Middle East to Western CountriesGlobal Bridges
This presentation will discuss the epidemiology, toxicology, and harms of waterpipes, as well as what further research is needed and the challenges in providing treatment for those interested in quitting. Presented as a webinar for Global Bridges on 26 February, 2014.
Dr. Bianco: Humo de segunda mano y riesgos cardiovascularesGlobal Bridges
Los profesionales de la salud, incluso aquellos relacionados con la salud cardiovascular, son conscientes
que el tabaco es uno de los principales factores de riesgo para muchas enfermedades, pero la
mayoría de ellos no han sido entrenados para reconocer al consumo de tabaco como una adicción,
no son conscientes de los mecanismos por los cuales el consumo de tabaco y la exposición al humo
del tabaco causan daños cardiovasculares. La mayoría de ellos tampoco han sido entrenados sobre
cómo abordar al paciente fumador en su práctica clínica diaria y como usar los medicamentos para el
tratamiento de la dependencia al tabaco. Esta conferencia tiene la intención de informar a los asistentes
sobre todos estos temas y estimularlos a obtener más información sobre ellos.
Going mobile: the potential of mHealth for tobacco dependence treatmentGlobal Bridges
Erik Augustson, PhD, MPH, is the Program Director of the Tobacco Control Research Branch of the National Cancer Institute. He serves on a number of national committees in the United States to improve population-based tobacco control such as the Department of Health and Human Services eHealth and mHealth Cessation Interventions committee, Smoking Cessation Subcommittee of the DHHS, the National Tobacco Control Strategy Committee and the North American Quitline Consortium. In addition, Dr. Augustson serves as the federal co-lead on the Smokefree.gov Initiative which represents the first web and mobile based cessation resource developed by the United States federal government.
During this webinar, Dr. Augustson discussed the use of mHealth for health behavior interventions, particularly in tobacco dependence. MHealth has been defined as “health related services delivered by mobile communication devices,” which can be in the form of SMS messaging, smartphone applications, or the mobile web. This webinar focused on text-message based interventions such as NCI’s SmokefreeTXT and the opportunity to implement such interventions at an international level. Dr. Augustson has worked on mHealth interventions not only in the United States but also in China and shared preliminary results from program evaluations and discussed the future potential of mobile interventions to treat tobacco dependence on a population level.
WEBINAR: Secondhand Smoke: The Science and Big Tobacco's SmokescreenGlobal Bridges
Webinar presented for Global Bridges on February 27, 2013
By Dr. Richard Hurt, Director of Mayo Clinic Nicotine Dependence Center
The science behind the harmful effects of tobacco smoke will be reviewed in detail, including results from Dr. Hiryama’s landmark study of female Japanese lung cancer patients who are non-smoking wives of smoking husbands, as well as the most recent study showing that smoke-free workplace laws are associated with a reduction in the incidence of acute myocardial infarctions.
The presentation also highlights Big Tobacco’s decades long public relations and media campaigns to deceive the public and create doubt and controversy about the harmful effects of secondhand smoke. These data come from previously secret tobacco industry documents made public as a result of the Minnesota Tobacco Trial of 1998 and the Department of Justice case that resulted in the conviction of Big Tobacco for violating the U.S. racketeering laws.
Global Bridges: Pharmacotherapy for Tobacco DependenceGlobal Bridges
May 2012: Dr. Richard Hurt, director of the Nicotine Dependence Center at the Mayo Clinic and chair of Global Bridges: Healthcare Alliance for Tobacco Dependence Treatment, discusses pharmacotherapy for tobacco dependence at a workshop in Jamaica.
Global Bridges: Farmacoterapia para la dependencia del tabaco (español)Global Bridges
On April 4, 2012, Global Bridges presented the webinar "Farmacoterapia para la dependencia del tabaco," which featured Dr. Richard Hurt, founder and director of the Mayo Clinic Nicotine Dependence Center and chair of Global Bridges: Healthcare Alliance for Tobacco Dependence Treatment.
Challenges in Expanding the Role of Health Care Providers and Delivering Trea...Global Bridges
Presentation by Jagdish Kaur, MBBS, Union Health Ministry, India, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Challenges in Implementing Tobacco Dependence Treatment in Jordan and the Eas...Global Bridges
Presentation by Feras Hawari, M.D., a pulmonologist and the Global Bridges regional director for the Eastern Mediterranean region, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Role of Health Care Systems and Providers in Changing Tobacco Dependence Trea...Global Bridges
Presentation by Gustavo Zabert, M.D., a pulmonologist and the Global Bridges regional director for the Latin American region, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Tobacco Dependence Treatment Training -- J. Taylor Hays, M.D.Global Bridges
Presentation by J. Taylor Hays, M.D., a Global Bridges co-investigator and professor of medicine at Mayo Clinic, at the Global Bridges Preconference at the 15th World Conference on Tobacco OR Health in Singapore.
Women and Smoking -- Ivana Croghan, Ph.D., Mayo ClinicGlobal Bridges
On March 8, 2012, Global Bridges presented the webinar "Women and Smoking," which featured Ivana Croghan, Ph.D., coordinator of the Mayo Clinic Nicotine Dependence Center's Research Program.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Introduction to Global Bridges -- Richard D. Hurt, M.D.
1.
2. Tobacco Is a Risk Factor for 6 of the
World’s 8 Leading Causes of Death
Hatched areas indicate proportions of deaths related to tobacco use.
3. Tobacco Use: An Escalating Epidemic
8
By 2030: 10
7
•Leading cause of death
millions of deaths
6
•10 million annual deaths
5
due to tobacco
•70% of those deaths will 4
4.9
occur in developing 3
countries 2
1
0
2000 2030
Developed Countries
Developing Countries
4. Treatment to Reduce Death &
Disease
Cumulative deaths from tobacco (millions)
520
500
Trend
400
300
220
200
100 70
0
1950 1975 2000 2025 2050
Year
Source: Peto et al
5. Cumulative deaths from tobacco (millions)
Impact of prevention
520
500 500
Trend
If smoking
uptake
400
halves by
2020
300
220
200
100 70
0
1950 1975 2000 2025 2050
Year
Source: Peto et al
6. Cumulative deaths from tobacco (millions) Impact of Treatment
520
500 500
Trend
If smoking
400 uptake halves
by 2020
300
halves by 2020 340
220 If adult smoking
200 halves by 2020
190
100 70
0
1950 1975 2000 2025 2050
Year
Source: Peto et al
8. Global Bridges Mission
Create and mobilize a global network
of healthcare providers and
organizations dedicated to advancing
effective tobacco dependence
treatment and advocating for
effective tobacco control policy.
www.globalbridges.org
9. Global Bridges Objectives
Build a network
Create opportunities to share treatment and advocacy
expertise among network members within and across
regions
Provide training
State-of-the-art, evidence-based training in tobacco
dependence treatment and advocacy
Article 14 implementation
Facilitate the implementation of FCTC Article 14 in every
nation
Sustain the mission
Ensure the long-term financial sustainability of the
initiative
10. Global Bridges Regional Partners
Latin America Region
Gustavo Zabert, MD – Regional Director
Middle East Region
Feras Hawari, MD – Regional Director
Africa Region
Lekan Ayo-Yusuf, BDS, MPH, PhD –
Regional Director
1
11. Key Accomplishments – 18 months
Quickly established 3 Regional
partnerships
& have begin work in additional regions
Trained over 600 HCPs from 26 countries
Over 6,800 person-hours of training
Impacting 24,000 tobacco-dependent patients
www.globalbridges.org
Collaborated with state, regional and/or
national governments to train HCPs in
accordance with A14
140% growth in membership database
1
12. Global Bridges Training Sessions
When
April
Where 2011
Puebla, Mexico
Sponsor
Sociedad Mexicana de Neumologia y Cirugia de Torax
Trainees
70
April Amman, Jordan King Hussein Cancer Center 15
May Neuquen, Argentina Sociedad Norpategonica de Nefrologia 15
June Amman, Jordan Jordan University of Science and Technology 31
July Asuncion, Paraguay Sociedad Paraguaya de Neumologia 85
August Ibadan, Nigeria Global Bridges 25
August Pretoria, South Africa Global Bridges 29
August Cordoba, Argentina Asociacion Argentina de Tabacologia 62
August Parana, Argentina Programa de Prevencion Enfermedades Cronicas de Entre Rios 39
September San Jose, Costa Rica IV Congreso Nacional de Cardiologia 43
September Lagos, Nigeria Global Bridges 29
October Lima, Peru 3er Congreso Regional de Tabaco O Salud 55
October Ecuador Cooperation with Argentina MoH to train officials 40
October Lusaka, Zambia University of Zambia 22
November South Africa Public Health Association of South Africa 37
November Kinshasa, DRC Global Bridges 33
December Tunisia Ministry of Health in Tunisia and Global Bridges 24
TOTAL TRAINEES 654
1
14. Themes for 2012
Define a Global “Core” CURRICULUM
including follow-up and evaluation
Broaden REACH within each Region
COMMUNICATE accomplishments and
opportunities
Identify and pursue additional
FUNDING
1
The basic epidemiology shows that over 500 million are likely to die from smoking related disease world wide in the first half of the 21 st Century.
This shows that the effect of ‘prevention’ of uptake makes little difference to the death toll expected in the first half of the 21 st Century. The problem is that the major health benefits of prevention are delayed for many years and prevention activity may simply cause a delay in initiation. Prevention is a worthy ideal, but it has proved difficult to achieve in practice and the evidence base for it is decidely shaky.
Smoking cessation can have a bigger impact – though a halving of smoking by 2020 is implausible. Smoking cessation directly treats those most at risk and the is a good evidence base to support it.